source
- Novo Nordisk sues Eli Lilly over alleged misleading obesity drug adsNovo Nordisk filed a lawsuit in a New Jersey federal court accusing Eli Lilly of deceptive advertising for its GLP-1 obesity medicines. The action follows a cease-and-desist request that asked Lil…
- Agios halts sickle cell drug program after disappointing phase 2 resultsAgios announced it is stopping development of its next‑generation pyruvate kinase activator, tebapivat, for sickle cell disease after a phase 2 trial failed to meet expectations. The study enrolle…